CClinicalTrials.gg
Not yet recruitingNCT06333301TIME-ZZZUpdated Mar 27, 2024

Translational Initiative to Map Epigenetics in Sleep

An observational study in Biological Aging, sponsored by Elysium Health. Not yet recruiting. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-27.

Sponsored by Elysium Health · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The primary aim of TIME-ZZZ is to explore the relationship between chronotype, incidence of depression and biological age, and whether individuals working "out-of-phase" with their chronotype are more likely to exhibit signs of depression and accelerated biological aging.

Read the detailed description

Understanding the relationship between chronotype, depression, and biological age is important in the field of sleep research and mental health. Sleep patterns and their alignment with an individual's internal body clock, or chronotype, have been increasingly recognized as influential factors in various aspects of well-being, including mental health and overall physiological aging. By conducting a study that investigates the potential correlation between chronotype, incidence of depression, and biological age, along with the impact of working "out-of-phase" with one's chronotype, the investigators can shed light on crucial aspects of sleep, mental health, and their interplay with biological aging.

02

Conditions studied

  • Biological Aging

Keywords

  • Sleep
  • Chronotype
03

In context

Lead sponsor

Elysium Health is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy adults

Inclusion criteria

  • Has taken an INDEX test within the last 3 months
  • Has registered at least 1 INDEX kit via the Elysium Health website
  • Able and willing to provide digital consent to the RSCF, and the TIME-ZZZ Research Subject Consent Form

Exclusion criteria

Exclusion Criteria:

  • Consent to participate not given
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • TIME-ZZZ

    Group will complete several surveys

    Other: Surveys

Interventions

  • OtherSurveys

    Group will complete several surveys

06

What researchers measure

Primary outcomes

  1. Effect of being "out of phase" with chronotype on biological age

    Determine whether individuals working "out-of-phase" with their chronotype (from TIME-ZZZ survey responses) exhibit higher rates of biological aging compared to those working within their chronotype

    Time frame: At baseline

Secondary outcomes

  1. Effect of Chronotype Alignment and Depression Risk in Relation to Rate of Aging

    Determine the effect of chronotype alignment and depression risk (from TIME-ZZZ surveys) on biological rate of aging

    Time frame: At baseline

  2. Identification of DNA methylation markers associated with chronotype

    Identify specific DNA methylation markers associated with chronotype (from TIME-ZZZ surveys) thereby providing potential insights into the epigenetic regulation of sleep-wake patterns

    Time frame: At baseline

  3. Identification of DNA methylation markers associated with depression

    Identify specific DNA methylation markers associated with depression (from TIME-ZZZ surveys) potentially shedding light on the underlying epigenetic mechanisms involved in the development and progression of depressive disorders.

    Time frame: At baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06333301
Lead sponsor
Elysium Health
Collaborators
University of Oxford
Responsible party
Sponsor
First posted
Mar 27, 2024
Start date
Apr 2024 (estimated)
Primary completion
Apr 2034 (estimated)
Completion
Apr 2034 (estimated)
Last update
Mar 27, 2024

Study contacts

Ryan W Dellinger, PhD
Contact
care@elysiumhealth.com
8882206436
Dayle Sampson, PhD
principal investigator · Elysium Health
Russell Foster, PhD
principal investigator · University of Oxford

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion